ReviewNeurosurgical review2022
Radiation therapy for atypical and anaplastic meningiomas: an overview of current results and controversial issues.
Review in Neurosurgical review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Multidisciplinary management of meningiomas in the era of precision oncology.Nature reviews. Clinical oncology · 2026Review
- Toxicities Associated with Adjuvant Radiation Therapy in Atypical Meningioma.Advances in radiation oncology · 2025Article
- Exploring the Role of Radiosurgery for Atypical Meningiomas: Addressing Suboptimal Local Control in High-Risk Patients.Advances in radiation oncology · 2025Article
- Initial management of newly diagnosed WHO grade 2-3 adult meningioma following surgery: results from the Dutch Brain Tumour Registry (2016-2021).Journal of neuro-oncology · 2024Article
- Comprehensive assessment of atypical and anaplastic pediatric meningiomas utilizing national cancer database: a retrospective cohort study.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024Article
- Controversies in neuro-oncology: Focal proton versus photon radiation therapy for adult brain tumors.Neuro-oncology practice · 2024Review
- Atypical and anaplastic meningiomas in the later decades of life: A national cancer database analysis.Acta neurochirurgica · 2024Article
- Article
- Fluorescence and immune-cell infiltration of nonneoplastic, postbrachytherapy brain tissue in 5-ALA-guided resection of recurrent anaplastic meningioma: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- The role of GammaTile in the treatment of brain tumors: a technical and clinical overview.Journal of neuro-oncology · 2024Review
- Improved quantification of tumor adhesion in meningiomas using MR elastography-based slip interface imaging.PloS one · 2024Article
- Drug Repositioning for Refractory Benign Tumors of the Central Nervous System.International journal of molecular sciences · 2023Review
- The role of particle radiotherapy in the treatment of skull base tumors.Frontiers in oncology · 2023Review
- NF2 mutations are associated with resistance to radiation therapy for grade 2 and grade 3 recurrent meningiomas.Journal of neuro-oncology · 2023Article
- Clinicopathological characteristics and prognostic factors of atypical meningiomas with bone invasion: a retrospective analysis of nine cases and literature review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
- Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 inNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are the most common intracranial tumors. Most meningiomas are WHO grade 1 tumors whereas less than one-quarter of all meningiomas are classified as atypical (WHO grade 2) and anaplastic (WHO grade 3) tumors, based on local invasiveness and cellular features of atypia. Surgical resection remains the cornerstone of meningioma therapy and represents the definitive treatment for the majority of patients; however, grade 2 and grade 3 meningiomas display more aggressive behavior and are difficult to treat. Several retrospective series have shown the efficacy and safety of postoperative adjuvant external beam radiation therapy (RT) for patients with atypical and anaplastic meningiomas. More recently, two phase II prospective trials by the Radiation Therapy Oncology Group (RTOG 0539) and the European Organisation for Research and Treatment of Cancer (EORTC 2042) have confirmed the potential benefits of fractionated RT for patients with intermediate and high-risk meningiomas; however, several issues remain a matter of debate. Controversial topics include the timing of radiation treatment in patients with totally resected atypical meningiomas, the optimal radiation technique, dose and fractionation, and treatment planning/target delineation. Ongoing randomized trials are evaluating the efficacy of early adjuvant RT over observation in patients undergoing gross total resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.